Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New published data - prostate cancer

02.02.2006


New published data show that bicalutamide (Casodex) 150mg plus radiotherapy significantly extends survival in men with locally advanced prostate cancer compared to radiotherapy alone



New data published in the February 2006 edition of the British Journal of Urology International (BJUI) confirm that bicalutamide 150mg improves the chance of survival by 35 per cent (hazard ratio = 0.65; 95% CI = 0.44 to 0.95, p = 0.03)1 in men with locally advanced prostate cancer (when the disease has spread into the capsule of the prostate or through the prostate into the surrounding tissue) when given bicalutamide 150mg as adjuvant to radiotherapy compared to radiotherapy alone. Bicalutamide 150mg is the only anti-androgen for which this has been shown.1

Also the data from the largest ever treatment study in prostate cancer show that in locally advanced disease, bicalutamide 150mg adjuvant to radiotherapy or radical prostatectomy reduces the risk of disease progression by 31 per cent (hazard ratio = 0.69; 95% CI = 0.58 to 0.82, p < 0.001) leading to a significant survival benefit of 35 per cent when used as adjuvant to radiotherapy.1, In addition, in men with locally advanced prostate cancer, when bicalutamide 150mg was given as monotherapy (alone) there was a 40 per cent reduction in risk, which extended survival free of progression by a median of 2.9 years, showing a trend towards improved survival.2


Commenting on the data, Dr Heather Payne, Consultant in Clinical Oncology, Middlesex Hospital, London stated: "A diagnosis of prostate cancer is truly devastating for the patient. A treatment that both extends a patient’s life and delays the recurrence of the disease whilst maintaining a man’s quality of life is the ultimate goal when managing this condition. This new data from the EPC Trial Programme demonstrates that bicalutamide 150mg meets these vital needs and will have this effect for men with locally advanced prostate cancer."

Results also confirm that treatment with bicalutamide 150mg significantly reduces the risk of bone metastases by 36 per cent in men with locally advanced prostate cancer compared to watchful waiting and by 23 per cent when added to radiotherapy or radical prostatectomy alone.2 Bone metastases are a symptom of disease progression and can include bone and back pain that can cause difficulty in walking and carrying out other daily activities and in more advanced cases can lead to spinal cord compression. By delaying disease progression, bicalutamide 150mg helps men with locally advanced prostate cancer to maintain an active lifestyle.

Patients with locally advanced prostate cancer have a significant risk of their disease progressing, seriously impacting quality of life. Therefore, therapies that improve progression-free survival whilst allowing patients to maintain a normal lifestyle are vital in managing the disease. In addition to improving progression-free survival, bicalutamide 150mg alone demonstrates equal efficacy to castration and provides patients with significant quality of life benefits. Compared with castration, bicalutamide 150mg provides better maintenance of physical capacity and sexual interest.3, Bicalutamide 150mg also maintains bone mineral density, which is lost with castration and is associated with an increased risk of fractures.

The EPC Trial Programme has followed 8,113 patients for an average of 7.4 years in 23 different countries. Patients will continue to be followed up for both disease progression and survival for a minimum period of 10 years after the last patient was enrolled into the study. The 3rd Analysis of the EPC Programme gives additional confirmation that bicalutamide 150mg is a proven treatment option for men with locally advanced prostate cancer delaying disease progression.

In the UK, bicalutamide (Casodex) 150 mg is indicated for patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO). Bicalutamide (Casodex) 150mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Bicalutamide (Casodex) 150mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

Rosie Allan | alfa
Further information:
http://www.bjui.org
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht The genes are not to blame
20.07.2018 | Technische Universität München

nachricht Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>